# Immix Biopharma, Inc. (IMMX)

> Source: Nexqual · https://nexqual.com/IMMX · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Immix Biopharma, Inc. (IMMX), nexqual.com/IMMX" · informational, not investment advice.

**Price:** USD 7.98 (-1.78% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 8.13 · day 7.84–8.36 · 52w 2.85–15.1 · market cap $662M · NCM

## Key facts
- Analysts: Buy (mean 1.57 on a 1–5 scale) (7 analysts), mean target USD 24.43 (range 17.4–30).
- Total return with dividends: 1Y +121.4% vs S&P 500 +14.8%; 5Y +99.5% vs S&P 500 +79.1%.
- Next earnings: 2026-11-06 (date not yet confirmed by the company), EPS estimate USD -0.19, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-06
- Dividend: IMMX paid no cash dividend in the last five years.
- Short interest: 15.17% of float (as of 2026-10-15), 6.2 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$1.4M | -$8.2M | -$16.1M | -$22.7M | -$30.0M | -$41.8M |
| Net income | -$24.4M | -$8.2M | -$15.4M | -$21.6M | -$29.4M | -$39.9M |
| EPS (diluted) | -$6.64 | -$0.59 | -$0.89 | -$0.76 | -$0.89 | — |
| Free cash flow | -$1.6M | — | -$11.4M | -$15.8M | -$24.7M | -$39.1M |
| Cash + short-term investments | $17.6M | $13.4M | $17.5M | $17.7M | $100M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 2.9x · FCF yield -5.91% · Earnings yield -6.03%

## Analysts
Consensus Buy (mean 1.57 on a 1–5 scale), 7 analysts; mean target USD 24.43 (low 17.4, high 30).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-29 | Needham | Target raised | Buy | $21 → $30 |
| 2026-09-15 | Mizuho | Target raised | Outperform | $15 → $26 |
| 2026-08-11 | Morgan Stanley | Target lowered | Overweight | $20 → $19 |
| 2026-08-10 | HC Wainwright & Co. | Target raised | Buy | $20 → $25 |
| 2026-07-22 | Needham | Initiated | Buy | $21 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-12-13) |
|---|---|---|
| Total return | +121.4% | +99.5% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +122.5% | +15.2% |
| Volatility (annualized) | 82.8% | 96.1% |
| Max drawdown | -44.9% (Aug 2026→Oct 2026) | -85.0% (Jan 2022→Nov 2022) |

## Dividends
IMMX paid no cash dividend in the last five years.

## Short interest
10,710,976 shares sold short, 15.17% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 9,621,660 shares (+11.3%). Days to cover: 6.2 (short shares ÷ average daily volume).

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · IOVA (Iovance Biotherapeutics, Inc.) USD 9.56 -35.45% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/IMMX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.19 | $-0.17 | −$0.01 | $0 | 7 |
| Next quarter (ends 2026-12-31) | $-0.20 | $-0.19 | −$0.01 | $0 | 7 |
| Current fiscal year (ends 2026-12-31) | $-0.72 | $-0.69 | −$0.03 | $0 | 8 |
| Next fiscal year (ends 2027-12-31) | $-0.95 | $-0.74 | −$0.21 | $27.9M | 8 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-06): ±25.3%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 22 | 130.3% | ±25.3% |
| 2027-02-19 | 113 | 151.9% | ±63.5% |
| 2027-05-21 | 204 | 126.3% | ±71.0% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.18 | −$0.18 | In line | — |
| — | Quarter ended Mar 31, 2026 | −$0.18 | −$0.21 | Beat +14.3% | — |
| — | Quarter ended Dec 31, 2025 | −$0.28 | −$0.16 | Miss −75.0% | — |
| — | Quarter ended Sep 30, 2025 | −$0.24 | −$0.19 | Miss −26.3% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).